Skip to content
Annika Bansal – Lifestyle
Author:
Dianthus Therapeutics, Inc.
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 1, 2026
Crystal Flush Lists the 7 Dangers of Ignoring Toe Fungus
April 24, 2026
Why Drugstore Products Aren’t Enough: Crystal Flush Explains the Value of a 2-Step Antifungal System
April 20, 2026
Crystal Flush Answers Customers’ Most Common Questions About Toe Fungus Care
April 17, 2026
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 6, 2026
The Crystal Flush Story: A Commitment to Helping People Manage Toe Fungus
March 27, 2026
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 12, 2026
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
March 10, 2026
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
March 9, 2026
Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results
March 9, 2026
←
Previous Page
1
2
3
Next Page
→